Filing Flows › EBR Systems (EBRCZ) › Guidance & outlook

EBR Systems (EBRCZ) guidance and outlook

EBR Systems' 10-Q filed Nov 9, 2026 makes 23 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 9, 2026

• Additionally, our historical results are not necessarily indicative of the results that may be expected for any period in the future.
• (“OUS”) that we would target after evaluating regulatory and reimbursement considerations.
• Our ability to grow our business will also depend on our ability to expand our customer base in existing or new target markets.
• We intend to make significant investments in our sales and marketing organization by increasing the number of sales representatives and expanding our marketing programs, in the U.S., to help facilitate further adoption among existing hospital accounts as well as broaden awareness of our products to new hospital accounts.
• Since inception, we have incurred significant net losses and expect to continue to incur net losses until we are able to generate sufficient revenue.
• There are a number of factors that have impacted, and we believe will continue to impact, our results of operations and growth.
• We recognize revenue upon the transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services, net of rebates.
• Specifically, revenue from the sale of WiSE is recognized at an amount that reflects the expected consideration upon notice that our products have been used in a surgical procedure.
• Our revenue is expected to continue to fluctuate in the future from quarter-to-quarter due to a variety of factors, including the success of our sales force in expanding adoption of WiSE in new hospitals and the number of physicians who are aware of and implant WiSE.
• Our gross margin has been and will continue to be affected by a variety of factors, primarily by our manufacturing costs, pricing, and the use of inventory that was previously expensed during our clinical trial, although we have fully utilized inventory that was previously expensed and going forward will receive no additional benefit to gross margin.
• We expect our gross margin will fluctuate from period to period based upon the factors described above.
• Research and development expenses also include costs of conducting our post-approval study, such as expenses associated with our clinical research organization, or CRO, who provided project management, outside service fees paid to third party consultants and contractors related to WiSE engineering, quality assurance and regulatory approval, as well as contract manufacturing of WiSE and allocated facility costs.

EBR Systems' latest quarter

Questions

What does EBR Systems expect?

Additionally, our historical results are not necessarily indicative of the results that may be expected for any period in the future. (“OUS”) that we would target after evaluating regulatory and reimbursement considerations. Our ability to grow our business will also depend on our ability to expand our customer base in existing or new target markets.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.